SEPTEMBER 16 DEADLINE ALERT: CAE, Inc. Shareholders Can Contact Block & Leviton to Learn More About Recovering Losses in Pending Litigation
12 sept. 2024 12h10 HE
|
Block & Leviton LLP
Block & Leviton reminds investors that a securities fraud lawsuit has been filed against CAE, Inc. Investors should contact the firm by September 16, 2024.
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
12 sept. 2024 08h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
SHAREHOLDER ALERT: Cibus, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
10 juin 2024 11h16 HE
|
Block & Leviton LLP
Cibus, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm.
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
08 mai 2024 07h00 HE
|
Cingulate Inc.
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
30 avr. 2024 05h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
KISS PR Announces Yahoo Finance Press Release Placement Best Practice for Its Customers in 2024
06 janv. 2024 21h50 HE
|
KISS PR Digital Marketing
DALLAS, Jan. 06, 2024 (GLOBE NEWSWIRE) -- KISS PR, a leader in digital marketing, content amplification and PR, today announced the launch of its enhanced service for 2024. This cutting-edge service...
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
01 déc. 2023 09h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
10 mai 2023 16h15 HE
|
Cingulate Inc.
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS...
Kaplan Fox Announces GERON CORPORATION (NASDAQ: GERN) INVESTOR ALERT – Important Claims Filing Deadline in Proposed Settlement in the Geron Securities Litigation is February 16, 2023
16 janv. 2023 21h32 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Jan. 16, 2023 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JULIA JUNGE and RICHARD JUNGE, on behalf ofthemselves and a class of similarly situated...
SQZ Biotechnologies News: Johnson Fistel Encourages SQZ Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
02 déc. 2022 06h05 HE
|
Johnson Fistel, LLP
SAN DIEGO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether SQZ Biotechnologies Company ("SQZ" or the "Company")...